CNS Oncology (ISSN: 2045-0907)
PublisherFuture Science Group
IF(Impact Factor)2018 Evaluation Pending
DescriptionTumors of the central nervous system (CNS) are the sixth most common form of cancer in adults and the most common form of solid cancer in children in the USA. Mortality rates remain high - primary CNS tumors are the second and fourth leading cause of cancer mortality in people under the ages of 34 and 54 years, respectively. Unfortunately, the prognosis for patients with malignant gliomas (the most common form of primary brain tumor) is largely unchanged from two decades ago, with survival being less than a year from diagnosis. Consequently, there is an urgent need to both develop effective new treatments and further the understanding of the biology for tumors arising in the CNS.
CNS Oncology addresses key issues and current understanding in the diagnosis, staging and treatment of disease by exploring the best patient-centered clinical research and presenting this information both directly, as clinical findings, and in practice-oriented formats of direct relevance in the clinic.
The journal presents this information using a clear and accessible presentation style. All articles are subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal's Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.
CNS Oncology provides oncologists and other health professionals with the latest findings and opinions on reducing the burden of this widespread disease. Recent research findings and advances in clinical practice in the field are reported and analyzed by international experts, and the importance of the most recent advances in molecular biology are explained.
Diagnosis and imaging
Pharmacoeconomics and outcomes research
Molecular biology of disease
Risk and prevention
Last modified: 2017-08-06 12:08:17
- No Archives